A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).
Anas Younes
Employment or Leadership Position - Memorial Sloan-Kettering Cancer Center
Honoraria - Bayer; Bristol-Myers Squibb; Celgene; Incyte; Janssen Research & Development; Millennium; Sanofi ; Seattle Genetics
Research Funding - Curis; Johnson & Johnson; Novartis
Pier Luigi Zinzani
No relevant relationships to disclose
Laurie Helen Sehn
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Peter W. M. Johnson
Consultant or Advisory Role - Johnson & Johnson
Honoraria - Johnson & Johnson
Research Funding - Janssen-Cilag
Randy D. Gascoyne
Consultant or Advisory Role - Celgene; Infinity Pharmaceuticals; Janssen; Seattle Genetics
Honoraria - Seattle Genetics
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Kevin M. Bellew
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen Pharmaceutical
Research Funding - Janssen Research & Development
Jessica Vermeulen
Employment or Leadership Position - Janssen
Stock Ownership - Janssen
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Steven Sun
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Louis M. Staudt
No relevant relationships to disclose
Wyndham Hopkins Wilson
No relevant relationships to disclose